Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genzyme Chemical Unit Goes To ICIG

by Michael McCoy
February 7, 2011 | A version of this story appeared in Volume 89, Issue 6

Genzyme has agreed to sell its pharmaceutical intermediates business to International Chemical Investors Group for an undisclosed sum. The business, in Liestal, Switzerland, makes chemically synthesized lipids, peptides, carbohydrates, and oligonucleotides. Under the deal, ICIG will supply Genzyme with materials needed to make eliglustat tartrate, a Genzyme drug in Phase III clinical trials for Gaucher’s disease, as well as other in-development treatments. In recent years, ICIG has purchased fine chemicals assets from AstraZeneca, Bristol-Myers Squibb, Cambrex, Rütgers, Clariant, and others.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.